News - Elan


Current filters:


Popular Filters

26 to 43 of 43 results

Elan to spin-off discovery science and Neotope Biosciences


Ireland-headquartered Elan Corp (NYSE: ELN) this morning revealed that its board of directors has approved…

BiotechnologyElanFinancialNeotope BiosciencesPharmaceutical

J&J and Pfizer drop bapineuzumab development for Alzheimer's


There was disappointing - though not really unexpected - news yesterday for US health care giant Johnson…

bapineuzumabElanJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

New analysis of risk stratification for Biogen and Elan's Tysabri


US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

Elan back in the black, boosted by Tysabri


Ireland headquartered biotech company Elan Corp (LSE: ELN) has reported its fourth-quarter 2011 results…


FDA updates Tysabri label relating to anti-JCV


The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Intellect Neurosciences appeals European patent decision


US neuro drug discovery firm Intellect Neurosciences (OTCBB: ILNS) says that it has filed an appeal regarding…

bapineuzumabBiotechnologyElanIntellect NeuroscienceLegalNeurologicalPatentsPfizerPharmaceutical

Elan links with Cambridge University for neurological drug research


Ireland-based neuroscience focused biotechnology company Elan Corp (NYSE: ELN) and the UK’s University…


Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

Alkermes completes Elan DT buy; signs manufacturing deal


US drugmaker Alkermes (Nasdaq: ALKS) says it has now completed its previously-announced acquisition of…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsPharmaceutical

Alkermes shareholders vote in favor of merger with Elan Drug Technology


Shareholders of USA-based Alkermes (Nasdaq; ALKS) have voted to approve the previously-announced $960…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsPharmaceutical

EU clears anti-JC virus risk labeling for Biogen and Elan’s Tysabri


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan (NYSE: ELN) said yesterday that the…

Biogen IdecBiotechnologyElanEuropeNeurologicalRegulationTysabri

Elan investing up to $50 million into the alliance with Proteostasis


Ireland-headquartered Elan Corp (NYSE: ELN) has entered a strategic business relationship to advance…

ElanMergers & AcquisitionsNeurologicalPharmaceuticalProteostasis TherapeuticsResearch

Elan Drug Tech to merge into Alkermes in $960 million deal to create CNS leader


US drugmaker Alkermes (Nasdaq: ALKS) and Ireland-based Elan Corp (NYSE: ELN) revealed this morning that…

AlkermesElanElan Drug TechnologiesMergers & AcquisitionsNeurologicalPharmaceutical

26 to 43 of 43 results

Back to top